^
    Back
    Association details:
    Biomarker:BRAF V600
    Cancer:Multiple Myeloma
    Drug:Mektovi (binimetinib) (MEK inhibitor) +
    Braftovi (encorafenib) (BRAF inhibitor, cRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Melanoma)
    New
    Excerpt:
    Encorafenib is indicated:...in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    LGX818 in combination with MEK162 in refractory or relapsed multiple myeloma patients with BRAFV600E or BRAFV600K Mutation

    Excerpt:
    ...Lancet 2014; 15: 538-548)3.Written confirmation of BRAFV600Emutation or BRAFV600K mutation in in the majority of myeloma cells, defined by positive IHC staining with mutations specific antibody of ≥ 50% in the respective biopsy and confirmed by DNA sequencing of the respective codon.4.Measurable disease, as defined as: • Measurable levels of myeloma paraprotein in serum (≥ 0.5 g/dL) or • urine (≥ 0.2 g/24 hours) or • FLC of involved light chain > 100mg/l and abnormal FLC-ratio5.Age ≥186.WHO performance status 0-3 (WHO=3 is allowed only when caused by MM and not by co-morbid conditions) (see Appendix III)7.Negative pregnancy test within 72 hours of inclusion (women of childbearing potential) 8. ...
    Trial ID:
    2014-004597-42
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2020
    Title:

    Safety and Preliminary Efficacy Results from a Phase II Study Evaluating Combined BRAF and MEK Inhibition in Relapsed/Refractory Multiple Myeloma (rrMM) Patients with Activating BRAF V600E Mutations: The GMMG-Birma Trial

    Published date:
    11/04/2020
    Excerpt:
    This phase II trial is evaluating the safety and efficacy of combined BRAF/MEK inhibition in rrMM pts with BRAF V600E mutation....The primary objective of this study was to demonstrate the therapeutic efficacy of encorafenib in combination with binimetinib....The ORR was 82% (lower limit of the 95% CI 56.4%, one-sided exact binomial test, p<0.0001) with 9/11 pts achieving partial response (PR) or better, 6/11 pts had at least a very good partial response (VGPR, 55%) and 3 pts reached (near) complete response (nCR/CR, 27%).